Cocrystal Pharma COCP 深 沪
等待开盘 07-14 09:30:00 美东时间
0.96
-0.050
-4.95%
华盛通- 最 高1.01
- 今 开1.01
- 成交量 2.79万股
- 最 低 0.96
- 昨 收 1.01
- 总市值 1323.60万
- 52周最高 2.67
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 0.8588
- 委 比 71.34%
- 总股本 1378.75万
- 历史最高 66.00
- 量 比 1.52
- 振 幅 4.95%
- 历史最低 0.8588
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Watching Cocrystal Pharma; Zacks-Small Cap Research Gives Stock $8 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_06012026_COCP_Bautz.pdf
06-01 23:07
Cocrystal Pharma's Direct-Acting Antivirals Demonstrate Pan-Viral Activity Against Multiple Viruses, Including Hantavirus, Bunyavirus And Influenza
Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenzaHantavirus and bunyavirus infections represent significant unmet
05-26 20:09
Cocrystal Pharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $225.000K
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 26.09 percent increase over losses of $(0.23) per share
05-15 20:09
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
Cocrystal Pharma Inc. reported updates on its antiviral pipeline, including the completion of enrollment in the first cohort of its Phase 1b challenge study for CDI-988 as a preventive and treatment for norovirus infection. The company also highlighted CDI-988's mechanism of action and clinical advancement at ICAR 2026 and received FDA Fast Track designation for the drug. Additionally, Cocrystal received an initial $225,000 of an SBIR NIH grant f...
05-15 12:00
Cocrystal Pharma Files $150M Shelf Offering To Sell Stock, Warrants, And Other Securities
$150,000,000 Cocrystal Pharma, Inc. Common StockPreferred StockWarrantsUnits Cocrystal Pharma, Inc. ("Cocrystal," the "Company," "we," "our," or "us") intends to offer and sell from time to time the
04-24 05:12
Why Cocrystal Pharma Shares Are Cooling Off Monday?
COCP stock is trading lower Monday morning. Learn why Cocrystal Pharma is seeing a pullback after receiving FDA Fast Track designation for CDI-988.
04-06 21:28
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Profusa (NASDAQ:PFSA) stock rose 48.6% to $0.86 during Thursday's regu...
04-03 01:05
Cocrystal Pharma Says FDA Grants Fast Track Designation To Its Direct-Acting Protease Inhibitor, CDI-988, Oral Antiviral Candidate Being Developed For Treatment And Prophylaxis Of Norovirus Infection
FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in worldwide economic
04-02 20:04
Cocrystal Pharma Q4 EPS $(0.17) Beats $(0.21) Estimate
Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 46.88 percent increase over losses of $(0.32) per share from
03-31 20:14
Cocrystal Pharma Announces First Subjects Dosed In Phase 1b Norovirus Challenge Study To Evaluate CDI-988 As Both Preventive And Treatment For Norovirus Infections
CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988No approved treatments or
03-09 20:05
